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Abstract
Today,	 monotherapy	 is	 the	 most	 common	 pharmacological	 treatment	 option	 for	
patients	 suffering	 from	 overactive	 bladder	 (OAB).	 Recent	 reports	 have	 indicated	
potential	benefits	of	combination	therapy,	using	a	muscarinic	antagonist	and	a	β3-
adrenoceptor	agonist.	This	may	be	of	particular	interest	for	therapy-resistant	patients	
with	OAB	and	concomitant	cystitis.	The	objective	of	the	current	study	was	to	assess	
how combination therapy affects bladder parameters in health and cystitis and if 
the	efficacy	of	the	drugs	can	be	linked	to	altered	release	of	nitric	oxide	(NO).	Rats	
were pretreated with either a combination of the muscarinic antagonist tolterodine 
and β3-selective	adrenoceptor	agonist	mirabegron	or	saline	for	10	days.	Forty-eight	
hours	prior	 to	assessing	micturition	parameters	 in	a	metabolic	cage,	 the	rats	were	
intraperitoneally	 injected	with	cyclophosphamide,	 causing	cystitis,	or	 saline.	Urine	
samples	were	collected	and	analyzed	for	NO	content.	Bladder	contractile	properties	
were assessed in an organ bath setup. Induction of cystitis led to bladder overactiv-
ity.	Combination	therapy	normalized	bladder	parameters.	Both	induction	of	cystitis	
and	drug	treatment	increased	the	release	of	NO.	The	innate	contractile	properties	of	
the bladder were unaffected by combination therapy. This study demonstrates posi-
tive	effects	of	combination	drug	therapy	on	symptoms	of	OAB,	possibly	indicating	
it	to	be	a	good	option	for	treatment	of	OAB	during	concomitant	cystitis.	It	remains	
to	be	determined	if	increased	release	of	NO	is	crucial	for	successful	pharmacological	
treatment of bladder overactivity during cystitis.
K E Y W O R D S
cyclophosphamide,	cystitis,	micturition	parameters,	mirabegron,	nitric	oxide,	tolterodine,	
urinary bladder
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1  | INTRODUC TION
Overactive	 bladder	 (OAB)	 is	 a	 common	 medical	 condition	 with	 a	
prevalence	of	approximately	16%,1 which is characterized by urgency 
and	 frequency,	often	 together	with	periods	of	nocturia	and	 incon-
tinence. The inflamed bladder has contractile properties that are 
somewhat	similar	to	that	of	OAB,	in	particular	during	interstitial	cys-
titis	(IC),	that	is,	bladder	inflammation	in	the	absence	of	bacterial	in-
fection.	Namely,	IC	is	apart	from	lower	abdomen	pain	also	commonly	
associated	with	frequency	and	urgency.	However,	even	though	there	
is sometimes an overlap in the pharmacological treatment of IC and 
OAB,	there	are	also	differences.	While	there	are	clear	guidelines	for	
the	treatment	of	OAB,	there	is	yet	to	emerge	a	worldwide	consensus	
and effective pharmacological treatment option for IC.
A	few	years	ago,	mirabegron,	an	adrenoceptor	agonist	selective	
for the β3-subtype,	was	approved	for	the	treatment	of	OAB.
2	At	the	
time,	the	by	far	most	common	pharmacological	therapy	against	OAB	
were	antimuscarinic	drugs.	However,	the	clinical	outcome	of	mono-
therapy with antimuscarinic drugs is often unsatisfactory and anti-
muscarinics	commonly	have	side	effects	such	as	dry	mouth,	dry	eyes,	
and	constipation	that	often	lead	to	discontinuation	of	the	treatment,	
despite	positive	effects	on	 the	OAB	symptoms.3	Leading	up	 to	 its	
approval,	both	preclinical	and	clinical	studies	had	shown	beneficial	
effects	of	mirabegron	against	urgency	and	frequency,4,5 with less re-
ported side effects.6	In	particular,	it	was	shown	to	often	be	effective	
for the rather large group of patients who were unresponsive to an-
timuscarinic treatment.7	Today,	monotherapy	is	still	by	far	the	most	
common	 treatment	 against	OAB.	 For	 instance,	 patients	 in	 Europe	
and	 North	 America	 are	 usually	 first	 prescribed	 an	 antimuscarinic	
drug,	and	only	 if	that	does	not	alleviate	the	symptoms	mirabegron	
is	used.	However,	recent	clinical	studies	have	shown	potential	ben-
efits of combination therapy with mirabegron and an antimuscarinic 
drug.8-10 This combination has therefore been suggested to have the 
potential	of	becoming	the	new	golden	standard	treatment	of	OAB.
Part	of	the	efficacy	of	mirabegron	has	been	suggested	to	depend	on	
induced	release	of	nitric	oxide	(NO),	tentatively	from	the	urothelium.11 
Even	though	it	has	been	shown	that	β-adrenoceptor	activation	causes	
the	release	of	NO	from	human	urothelial	cells,12,13 the actual effect of 
mirabegron	on	NO	release	in	the	bladder	remains	to	be	determined	in	
conclusive studies. Considering previous findings that antimuscarinics 
could	potentially	decrease	the	release	of	NO,	mainly	in	a	state	of	cysti-
tis,14,15 and that this could be part of the reason for their lack of efficacy 
in	a	state	of	concomitant	bladder	overactivity	and	 inflammation,	 the	
exact	role	that	mirabegron	has	on	NO	release	is	highly	interesting.
This study aims to assess the effects of treatment with combina-
tion	drug	therapy	commonly	used	 in	the	treatment	of	OAB.	 In	par-
ticular,	it	is	wondered	if	combination	therapy	leads	to	altered	release	
of	NO.	 It	was	also	wondered	how	the	combination	therapy	affects	
bladder	parameters	in	health	and	cystitis.	For	this	purpose,	to	obtain	
steady	state,	rats	were	pretreated	with	either	saline	or	a	combination	
of	 tolterodine	 (muscarinic	 antagonist)	 and	mirabegron	 (β3-selective	
adrenoceptor	agonist)	for	10	days.	Forty-eight	hours	prior	to	assess-
ment	of	bladder	parameters	in	a	metabolic	cage,	rats	from	each	group	
were	given	an	intraperitoneal	bolus	dose	of	either	saline,	serving	as	
control,	 or	 cyclophosphamide	 (CYP),	 a	 cytostatic	 drug	 commonly	
used to induce cystitis. During the metabolic cage assessment pe-
riod,	 urine	 samples	 were	 collected	 and	 subsequently	 analyzed	 for	
NO	content.	After	the	assessment	period,	the	rats	were	euthanized,	
the	bladders	were	excised,	and	full-thickness	strips	of	bladder	tissue	
were used for contractile studies in an organ bath setup.
2  | MATERIAL AND METHODS
2.1 | Animals
This study was approved by the local ethics committee at the 
University	of	Gothenburg	(ethical	permit	196-13).	A	total	of	32	male	
Sprague-Dawley	 rats	 (285-495	 g,	 10-16	 weeks)	 purchased	 from	
Charles	River	were	used	in	this	study.	All	experimental	procedures	
followed the requirements stated in the ethical permit and had full 
adherence	to	ARRIVE	and	BJP	guidelines.	The	species	was	chosen	
since it is phylogenetically close enough to man to allow for it to be 
translational and for the fact that most lower urinary tract animal 
models,	including	those	previously	performed	by	the	authors,	have	
been	developed	in	rats.	Extensive	and	relevant	data	therefore	exist	
for valid comparisons to be made.
2.2 | Study design
Each	 animal	 was	 randomized	 to	 be	 pretreated	 twice	 daily	 for	
10	days	with	either	 saline	 (0.9%	NaCl	 in	3%	DMSO,	1	mL	kg−1 per 
day s.c.,	serving	as	control)	or	a	combination	of	tolterodine	(in	saline;	
0.05 mg kg−1 per day s.c.;	1	mL	kg−1	per	day)	and	mirabegron	(in	sa-
line	with	6%	DMSO;	0.6	mg	kg−1 per day s.c.;	1	mL	kg−1	per	day).	The	
doses were chosen to match those recommended for the treatment 
of	OAB	patients	and	the	time	period	was	chosen	to	ensure	reaching	
steady	state	of	the	drugs.	Forty-eight	hours	prior	to	assessment	of	
bladder	parameters	 in	a	metabolic	cage,	half	of	the	animals	 in	each	
group were randomized to be treated with a bolus dose of either sa-
line	(1	mL	kg−1 i.p),	serving	as	control,	or	the	antineoplastic	drug	CYP	
(in saline; 100 mg kg−1 i.p,),	 in	order	to	 induce	experimental	cystitis	
(Figure	1).	This	generated	four	groups	(saline	pretreated	controls,	drug	
pretreated	controls,	saline	pretreated	inflamed,	and	drug	pretreated	
inflamed)	with	eight	animals	in	each	group.	After	a	16-h	period	in	the	
metabolic	cage,	the	animals	were	euthanized	by	an	overdose	of	pen-
tobarbitone	(100-150	mg	kg−1 i.p;	pentobarbital;	APL),	in	accordance	
with	the	requirements	stated	in	the	ethical	permit,	and	their	bladders	
were	excised	for	further	assessment	in	an	organ	bath	setup	(n	=	6).
2.3 | Metabolic cage
After	 completion	 of	 the	 drug	 treatment	 protocol,	 micturition	 pa-
rameters were collected by placing the animals in a metabolic cage 
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with	free	access	to	water.	During	a	16-h	observation	period,	urine	
samples from each rat were collected in a graded bottle and subse-
quently	stored	at	−80°C	and	used	for	further	(voltammetric)	analy-
sis.	A	WFL30-40B416	laser	Doppler	(SICK)	placed	near	the	bottom	
of	the	metabolic	cage	continually	registered	each	expelled	drop	of	
urine allowing for micturition parameters to be calculated. The num-
ber of micturitions was determined by visual analysis of the regis-
tered	data.	By	division	with	the	total	time	(16	hours),	the	number	of	
micturitions per hour was calculated. To calculate the volume per 
micturition,	the	total	volume	was	divided	by	the	number	of	mictu-
ritions. Total water consumption was noted for each animal. Data 
were	recorded	using	a	MP150WSW	data	acquisition	system	and	the	
AcqKnowledge	3.8.1	software	(BioPac	Systems).
2.4 | Voltammetric measurement of nitrite
Urine	samples	stored	at	−80°C	were	shipped	from	the	University	of	
Gothenburg	to	the	University	of	Brighton	and	analyzed	in	a	blinded	
fashion.	Upon	 analysis,	 samples	were	 allowed	 to	 thaw	 on	 ice	 and	
then	vortexed	for	2	minutes	prior	to	nitrite	measurements.	The	ex-
perimental	setup	consisted	of	a	2-mm	platinum	working	electrode,	an	
Ag|AgCl	reference	electrode,	and	a	platinum	wire	counter	electrode,	
used	as	a	three	electrode	system	(CH	Instruments).	Measurements	
were conducted using a 630b potentiostat with a faraday cage (CH 
Instruments).	Data	acquisition	and	analysis	were	achieved	using	the	
CH	Instruments	built-in	software.
For	the	measurement	of	nitrite	standard	and	urine	samples,	dif-
ferential	pulse	voltammetry	 (DPV)	was	utilized.	The	potential	win-
dow	was	between	0.4	and	1.2	V,	with	a	pulse	width	of	0.06	seconds	
and	amplitude	of	0.05	V.	The	scan	rate	was	0.004	V.	Initially,	DPV	
measurements	 were	 conducted	 using	 0.5-4	 mmol	 L−1 sodium ni-
trite	 in	 0.1	mol	 L−1	 phosphate-buffered	 saline	 (PBS)	 to	 generate	 a	
calibration	response.	Urine	samples	were	then	measured,	with	the	
electrode being polished between measurements. The current am-
plitude	at	the	oxidation	peak	potential	for	nitrite	was	obtained	from	
all the urine samples and converted to concentration by correlation 
to the calibration response. The measured levels of nitrite are gener-
ally	considered	to	correspond	to	the	levels	of	NO	in	urine.
2.5 | Organ bath experiments
Most	excised	bladders	were	used	for	measurement	of	contractile	
properties.	Upon	removal	of	the	bladder	tissue,	each	specimen	was	
visually	 examined	 for	 typical	 signs	 of	 inflammation,	 that	 is,	 red-
ness	and	increased	wall	thickness.	All	bladders	from	animals	pre-
treated	with	CYP	displayed	macroscopical	 signs	of	 inflammation.	
Each	bladder	was	cut	along	the	opposite	side	of	the	trigone	area	
from	the	urethral	opening	to	the	apex.	The	bladders	were	carefully	
F I G U R E  1  Experimental	design.	Rats	were	treated	for	10	days	with	either	vehicle	(A,	C;	saline;	1	mL	kg−1 per day s.c.)	or	a	drug	
combination	(B,	D;	mirabegron	0.6	mg	kg−1 per day s.c.	and	tolterodine	0.05	mL	kg−1 per day s.c.).	Forty-eight	hours	prior	to	spending	16	hour	
in	a	metabolic	cage,	the	rats	received	an	intraperitoneal	injection	with	either	saline	(A,	B;	4	mL	kg−1)	or	cyclophosphamide	(C,	D;	CYP;	
100 mg kg−1)	in	order	to	induce	cystitis
(A) 16 h10 days
48 h
Saline (4 mL/kg i.p.)
Vehicle (saline 1mL/kg/day s.c.)
Metabolic cage
(B) 16 h10 days
48 h
Saline (4 mL/kg i.p.)
Treatment (mirabegron 0.6 mg/kg/day s.c., tolterodine 0.05 mg/kg/day s.c.)
Metabolic cage
(C) 16 h10 days
48 h
CYP (100 mg/kg i.p.)
Vehicle (saline 1mL/kg/day s.c.)
Metabolic cage
(D) 16 h10 days
48 h
CYP (100 mg/kg i.p.)
Metabolic cage
Treatment (mirabegron 0.6 mg/kg/day s.c., tolterodine 0.05 mg/kg/day s.c.)
Urine sampling
Urine sampling
Urine sampling
Urine sampling
Organ bath
Organ bath
Organ bath
Organ bath
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pinned	with	the	urothelial	side	up	and	full-thickness	bladder	strips	
(6	 ×	 2	mm)	were	 prepared	 according	 to	 a	 standard	 procedure.16 
Thereafter,	the	detrusor	strips	were	mounted	in	25-mL	organ	baths	
containing	Krebs	 solution	 (NaCl	118	mmol	L−1,	KCl	4.6	mmol	L−1,	
KH2PO4	1.15	mmol	L
−1,	MgSO4	1.15	mmol	L
−1,	NaHCO3 25 mmol 
L−1,	glucose	5.5	mmol	L−1,	and	CaCl2	1.25	mmol	L
−1	in	distilled	water)	
at	37°C	and	gassed	with	5%	CO2 in O2 to maintain an appropriate 
pH	level.	The	strips	were	stretched	to	10	mN	and	let	to	equilibrate	
for 45 minutes. The baseline tension was continuously adjusted 
during	the	experiment	to	remain	between	5	and	7	mN.
At	the	beginning	of	each	experiment,	a	high	K+	Krebs	solution	(KCl	
124	mmol	L−1,	KH2PO4	1.15	mmol	L
−1,	MgSO4	1.15	mmol	L
−1,	NaHCO3 
25	mmol	L−1,	glucose	5.5	mmol	L−1,	and	CaCl2	1.25	mmol	L
−1 in distilled 
water)	was	administered	 in	order	 to	assess	 tissue	viability.	All	drugs	
were administered to the organ baths at a volume of 125 μL.	The	mus-
carinic	 agonist	methacholine	 (MeCh)	was	added	cumulatively	 to	 the	
baths (10−8-10−4	mmol	L−1).	After	an	initial	MeCh	dose-response	series,	
to	assess	possible	functional	 influence	of	NO,	Nω-nitro-L-arginine	 (L-
NNA;	10−4	mmol	L−1),	an	inhibitor	of	NO	synthase,	was	added	to	the	
baths.	After	an	 incubation	period	of	20	minutes,	the	MeCh	dose-re-
sponse	series	was	run	once	more.	At	the	end	of	the	experiment,	tissue	
viability	was	again	 tested	by	 the	addition	of	high	K+	Krebs	 solution.	
Data	were	 recorded	 using	 a	MP36	data	 acquisition	 system	 and	 the	
AcqKnowledge	3.8.1	software	(BioPac	Systems).
2.6 | Data analysis and statistical calculations
The data and statistical analysis comply with the recommenda-
tions	 on	 experimental	 design	 and	 analysis	 in	 pharmacology.17 
Statistical analysis was undertaken only for studies where each 
group	size	was	at	least	n	=	5.	The	group	sizes	were	calculated	using	
the	G*Power	software	ver	3.1.9.4.18 The calculation was based on 
an	expected	effect	size	of	2.5	(estimated	from	data	from	a	previ-
ous study 13),	α	 =	 .05,	1-β	 =	 .95,	 and	 an	 allocation	 ratio	of	1.	To	
avoid	underpowering,	that	 is,	to	compensate	for	biological	varia-
tion,	a	sample	size	of	n	=	8	was	chosen	for	the	current	study.	The	
declared group size is the number of independent observations 
and statistical analysis was done using these independent values. 
All	values	were	included	in	the	analysis	and	presentations,	includ-
ing possible outliers. Statistical significance was determined by 
two-way	 analysis	 of	 variance	 (ANOVA)	 followed	 by	 Tukey's	 cor-
rection	for	multiple	comparisons.	Post	hoc	tests	were	conducted	
only	 if	F	 in	ANOVA	achieved	 the	 level	of	 statistical	 significance.	
Statistical significance was regarded for p-values	 <.05.	Data	 are	
presented	as	mean	±	SEM.	Graphs	were	generated	and	parameters	
computed	using	GraphPad	Prism	8.1	(GraphPad	Software	Inc).
2.7 | Materials
All	substances	and	materials	were	purchased	from	Sigma-Aldrich	un-
less otherwise stated.
Tolterodine	 tartrate	 (Tocris),	 mirabegron	 (AdooQ	 Bioscience),	
cyclophosphamide	 monohydrate,	 pentobarbital	 sodium	 (pento-
barbitone;	 APL,	 Gothenburg,	 Sweden),	 dobutamine	 hydrochloride	
(Tocris),	 acetyl-β-methylcholine	 chloride,	 Nω-nitro-L-arginine	 (L-
NNA),	 sodium	 chloride,	 potassium	 chloride,	 potassium	dihydrogen	
phosphate,	magnesium	 sulfate,	 sodium	bicarbonate,	D-(+)-glucose,	
calcium	chloride	dehydrate,	and	dimethyl	sulfoxide	(DMSO).
3  | RESULTS
3.1 | Effects of drug treatment and cystitis on 
bladder parameters
In	comparison	to	controls,	induction	of	cystitis	with	CYP	caused	a	sig-
nificant increase in micturition frequency (1.03 ± 0.23 and 1.86 ± 0.18 
mict h−1	 in	saline	pretreated	controls	and	saline	pretreated	inflamed,	
respectively;	 Figure	 2).	 Combination	 drug	 therapy	 with	 tolterodine	
and mirabegron normalized the number of micturitions per hour 
(1.86	±	0.18	and	1.07	±	0.09	 in	saline	pretreated	 inflamed	and	drug	
pretreated	 inflamed,	 respectively;	 Figure	 2).	Meanwhile,	 micturition	
frequency was not affected by combination drug treatment in healthy 
rats	(1.03	±	0.23	and	0.94	±	0.15	mict	h−1 in saline pretreated and drug 
pretreated	control	rats,	respectively;	Figure	2).
Induction	 of	 cystitis	 with	 CYP	 caused	 a	 substantial	 but	 nonsig-
nificant decrease of the volume per micturition (1.03 ± 0.14 and 
F I G U R E  2  Number	of	micturitions	per	hour	(frequency)	in	
healthy	(control)	rats	and	rats	treated	with	CYP	in	order	to	induce	
cystitis.	In	both	groups,	animals	were	pretreated	for	10	days	with	
either	saline	(□;	1	mL	kg−1 per day s.c.)	or	a	combination	drug	
treatment ( )	against	OAB	consisting	of	the	muscarinic	antagonist	
tolterodine	(0.05	mL	kg−1 per day s.c.)	and	the	β3-adrenoceptor	
agonist	mirabegron	(0.6	mL	kg−1 per day s.c.).	Induction	of	cystitis	
caused	an	increase	in	frequency,	which	could	be	normalized	by	
OAB	drug	treatment.	Statistical	comparisons	are	made	by	two-way	
ANOVA	followed	by	Tukey's	correction	for	multiple	comparisons.	
n	=	8	in	all	groups.	*P	<	.05
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0.74	±	0.06	mL	in	saline	pretreated	controls	and	saline	pretreated	in-
flamed,	 respectively;	Figure	3).	 In	 inflamed	rats,	combination	therapy	
led to a significant increase in the volume per micturition (0.74 ± 0.06 
and	1.21	±	0.12	mL	in	saline	pretreated	inflamed	and	drug	pretreated	in-
flamed,	respectively;	Figure	3)	to	a	level	similar	to	that	observed	in	con-
trols.	A	similar	increase	in	the	micturition	volume	could	not	be	observed	
in	controls	upon	drug	treatment	(1.03	±	0.14	and	0.95	±	0.11	mL	in	saline	
pretreated	and	drug	pretreated	control	rats,	respectively;	Figure	3).
3.2 | Effects of drug treatment and cystitis on water 
consumption and total urine production
No	 significant	 differences	 could	 be	 detected	 between	 any	 of	 the	
groups with regard to water consumption neither due to drug treat-
ment	nor	 induction	of	cystitis,	 even	 though	 there	was	a	 tendency	
that	 CYP-treated	 animals	 drank	 more	 (Table	 1).	 However,	 the	 in-
terindividual variations in water consumption were high among all 
groups.	A	similar	tendency	of	an	increased	total	volume	of	micturi-
tion	can	be	seen	in	the	CYP-treated	groups.	This	is	likely	due	to	the	
somewhat higher water intake in these groups.
3.3 | Effects of drug treatment and cystitis on the 
levels of nitric oxide
Measured	 by	 voltammetry	 as	 amount	 of	 nitrite	 in	 urine,	 treatment	
with	 the	combination	therapy	caused	an	 increased	release	of	NO	 in	
the	urinary	bladder	both	 in	healthy	and	 inflamed	rats	 (25.86	±	1.96,	
48.54	±	2.88,	and	53.42	±	4.28	µmol	L−1	in	saline	pretreated	controls,	
drug	pretreated	controls,	and	drug	pretreated	inflamed,	respectively;	
Figure	4).	Further,	induction	of	bladder	inflammation	per	se	increased	
the	release	of	NO	(25.86	±	1.96	and	42.99	±	5.51	µmol	L−1 in saline pre-
treated	controls	and	saline	pretreated	inflamed,	respectively;	Figure	4).
3.4 | Effects of drug treatment and cystitis on 
detrusor contractility
In	an	organ	bath	setup,	no	significant	differences	in	MeCh-induced	
contraction could be detected between bladder strips from sa-
line	or	drug	pretreated	 rats,	neither	 in	 control	nor	 inflamed	 tissue	
(Figure	5).	Likewise,	addition	of	the	NO	synthase	blocker	L-NNA	did	
not	significantly	shift	the	contraction-response	curve,	even	though	
there was a tendency for an increase in the saline pretreated in-
flamed	 group	 (Figure	 5B).	 In	 general,	 MeCh-induced	 contraction	
was	slightly	greater	in	healthy	(control)	strips	than	inflamed	bladder	
strips	(Figure	5A	and	B,	respectively).
4  | DISCUSSION AND CONCLUSIONS
In	the	current	study,	induction	of	cystitis	with	CYP	led	to	changes	
in micturition parameters causing a state of bladder overactivity. 
This is in line with previous studies.19,20 Combination therapy with 
mirabegron and tolterodine normalized the altered micturition 
parameters,	without	 affecting	 the	micturition	pattern	 in	 healthy	
rats.	Simultaneously,	 the	drug	 treatment	did	not	 significantly	af-
fect water intake or total volume of produced urine over a period 
of	16	hours,	even	though	CYP-treated	rats	tended	to	drink	more	
and therefore produce a larger total volume of urine than con-
trols.	However,	even	 though	a	 somewhat	 larger	water	consump-
tion	could	contribute	to	a	change	in	the	urodynamics,	the	overall	
changes of the micturition parameters are evident and agree well 
with	 previously	 reported	 changes	 occurring	 in	 CYP-pretreated	
rats.
Positive	 effects	 of	 combination	 therapy	 have	 been	 shown	 in	
a	previous	preclinical	study,	which	examined	the	acute	effects	of	
treatment with mirabegron and antimuscarinics on cystometric 
parameters in conscious female rats with bladder overactivity in-
duced	by	oxotremorine	methiodide.21 That study concluded that 
combination therapy significantly improved cystometric parame-
ters as compared to monotherapy with either drug alone. Superior 
clinical outcome of combination therapy as compared to mono-
therapy	has	also	been	shown	in	a	clinical	study	on	OAB	patients.9 
The current study demonstrates similar positive effects of com-
bination therapy on symptoms of bladder overactivity in a state 
of	concomitant	cystitis.	However,	it	needs	to	be	pointed	out	that	
CYP-induced	cystitis	 is	 a	model	of	 acute	 inflammation,	different	
from	chronic	forms	of	bladder	inflammation	seen	in	patients,	most	
commonly IC.22
F I G U R E  3  Volume	per	micturition	in	healthy	(control)	rats	and	
rats	treated	with	CYP	in	order	to	induce	cystitis.	In	both	groups,	
animals	were	pretreated	for	10	days	with	either	saline	(□;	1	mL	kg−1 
per day s.c.)	or	a	combination	drug	treatment	( )	against	OAB	
consisting	of	the	muscarinic	antagonist	tolterodine	(0.05	mL	kg−1 
per day s.c.)	and	the	β3-adrenoceptor	agonist	mirabegron	
(0.6	mL	kg−1 per day s.c.).	Induction	of	cystitis	caused	a	decrease	in	
micturition	volume,	which	was	normalized	by	OAB	drug	treatment.	
Statistical	comparisons	were	made	by	two-way	ANOVA	followed	
by	Tukey's	correction	for	multiple	comparisons.	n	=	8	in	all	groups.	
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While	studies	on	the	relaxatory	effects	of	mirabegron	in	human	and	
rat corpus cavernosum or human and rabbit prostate could not show 
any	mechanistic	 involvement	of	NO,23,24 others have suggested that 
NO	is	part	of	the	relaxatory	mechanism	of	mirabegron	in	the	bladder.11 
The current study shows that combination treatment causes release of 
NO	in	the	urinary	bladder.	It	is	unlikely	that	this	increased	release	is	due	
to	the	action	of	tolterodine	as	previous	studies	have	shown	that,	if	any-
thing,	antagonism	of	muscarinic	 receptors	attenuates	NO	release,	 in	
particular,	in	a	state	of	inflammation.14	Thus,	it	is	likely	that	mirabegron	
causes	the	release	of	NO.	Further,	the	data	show	that	induction	of	cys-
titis	per	se	leads	to	an	increased	release	of	NO.	This	is	expected	as	NO	
is	commonly	 involved	 in	 inflammatory	processes	and	NO	previously	
has been attributed to an increased role in the urinary bladder during 
CYP-induced	cystitis.14,25	However,	it	is	not	possible	to	detect	a	signifi-
cantly	increased	release	of	NO	in	a	state	of	cystitis	during	combination	
therapy	as	compared	to	saline	treated	rats	with	CYP-induced	cystitis.	
Considering that the micturition parameters are normalized by com-
bination	therapy,	this	could	indicate	that	the	increased	release	of	NO	
during	cystitis	is	not	crucial	to	the	mechanism	of	action	of,	mainly,	mi-
rabegron.	However,	several	other	possible	explanations	exist.	For	one,	
it	is	possible	that	the	production	capacity	is	maximized	in	a	state	of	in-
flammation,	rendering	it	impossible	for	mirabegron	to	further	increase	
the	release	of	NO.	Another	possible	explanation	is	that	the	inflamma-
tory	response	upon	treatment	with	CYP	is	attenuated	by	the	present	
combination	therapy.	In	such	a	scenario,	the	measured	release	of	NO	
in the inflamed bladders from rats under combination therapy would 
mainly	be	attributable	to	mirabegron.	A	third	possible	explanation	 is	
that	inflammation	per	se	is	increasing	the	release	of	NO,	but	that	the	
drugs included in the combination therapy are balancing each other 
out	with	regard	to	NO	release.	Namely,	that	tolterodine	is	decreasing	
but	mirabegron	is	increasing	the	release	of	NO.	This	would	be	in	line	
with the findings in previous studies.14,26	However,	for	conclusive	ev-
idence,	this	would	need	to	be	examined	in	animals	treated	with	only	
mirabegron	or	tolterodine,	respectively.
The	unchanged	responses	of	isolated	full-thickness	bladder	strips	
to methacholine in an organ bath setup demonstrate that treatment 
with a combination of tolterodine and mirabegron does not signifi-
cantly	alter	the	innate	contractile	properties	of	the	detrusor,	at	least	
not over a period of 10 days. This may seem surprising when consid-
ering that another study in rat has demonstrated an increased bladder 
sensitivity	to	muscarinic	agonists	as	well	as	an	increased	expression	
of muscarinic receptors upon induction of overactivity.27	However,	
in	that	study,	overactivity	was	induced	by	treatment	with	streptozo-
tocin,	which	induces	a	diabetic	state	in	the	bladder.	Preliminary	ex-
periments	do	not	indicate	altered	expression	of	muscarinic	receptors	
in	the	current	study	(data	not	shown).	However,	future	studies	should	
address	this	issue	quantitatively.	For	obvious	reasons,	alterations	in	
receptor	expression	and	 innate	contractility	over	 longer	periods	of	
combination drug therapy or in combination with other methods of 
induction	of	bladder	overactivity	cannot	be	excluded.
In	accordance	with	previous	studies,	 induction	of	 inflammation	
with	CYP	attenuates	the	contractile	cholinergic	response	of	rat	de-
trusor.25	 Further,	 as	previously	 shown,28 induction of cystitis with 
CYP	gives	rise	to	certain	histological	changes,	that	is,	thickening	of	
the bladder wall due to swelling and urothelial proliferation. This 
was obvious in the present study as well when studying the tissue 
 
Control 
- saline
Control 
- treatment
Inflamed 
- saline
Inflamed 
- treatment
Total	volume	of	micturition	(mL	
per	16	h	±	SD)
15.5 ± 8.6 14.6 ± 6.0 21.8 ± 11.0 23.0 ± 14.1
Water	consumption	(mL	per	
16	h	±	SD)
16.6 ± 10.5 14.0	±	9.7 25.2 ± 17.8 23.1 ± 15.4
Note: In	both	groups,	animals	were	pretreated	for	10	days	with	either	saline	(1	mL	kg−1 per day s.c.)	
or	a	combination	drug	treatment	against	OAB	consisting	of	the	muscarinic	antagonist	tolterodine	
(0.05	mL	kg−1 per day s.c.)	and	the	β3-adrenoceptor	agonist	mirabegron	(0.6	mL	kg
−1 per day s.c.).	
No	significant	differences	could	be	detected	by	statistical	comparisons	using	two-way	ANOVA.	
n	=	8	in	all	groups.
TA B L E  1   Total volume of micturition 
and water consumption in healthy 
(control)	rats	and	rats	treated	with	CYP	in	
order to induce cystitis
F I G U R E  4  Levels	of	nitrite	(corresponding	to	levels	of	NO)	
in	urine	from	healthy	(control)	rats	and	rats	treated	with	CYP	in	
order	to	induce	cystitis.	In	both	groups,	animals	were	pretreated	
for	10	days	with	either	saline	(□;	1	mL	kg−1 per day s.c.)	or	a	
combination drug treatment ( )	against	OAB	consisting	of	the	
muscarinic	antagonist	tolterodine	(0.05	mL	kg−1 per day s.c.)	and	the	
β3-adrenoceptor	agonist	mirabegron	(0.6	mL	kg
−1 per day s.c.).	Both	
combination drug treatment and cystitis per se caused a significant 
increase	in	the	levels	of	NO.	Measurements	were	conducted	by	
voltammetry and concentration of nitrite corresponds to levels of 
NO	in	urine.	Statistical	comparisons	are	made	by	two-way	ANOVA	
followed	by	Tukey's	correction	for	multiple	comparisons.	n	=	8	in	all	
groups. *P	<	.05
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under	a	 light	microscope	 (data	not	shown).	 Interestingly,	prolifera-
tion of the urothelium was not as prominent in inflamed tissues from 
rats	that	underwent	combination	therapy.	Notably,	mirabegron	has	
previously been shown to have protective effects in a rat model for 
chronic ischemic bladder.29	However,	in	order	to	draw	more	certain	
conclusions regarding the potential protective effects of mirabe-
gron,	this	needs	to	be	studied	quantitatively	in	animals	undergoing	
monotherapy.
In order to ensure correct blood concentration of tolterodine and 
mirabegron	at	the	time	of	measurement	of	micturition	parameters,	it	
was imminent that the rats were pretreated with the drugs for a sub-
stantial time period. This inevitably led to the drugs being present at 
the	time	of	induction	of	cystitis.	Therefore,	the	possibility	that	the	
combination therapy had a dampening effect on the development 
of	 cystitis	 cannot	 be	 disregarded.	 Likewise,	we	 cannot	 ignore	 the	
possibility	of	this	affecting	micturition	parameters	and	NO	release	
differently in a clinical situation in which cystitis typically develops 
before drug treatment is initiated.
In	conclusion,	combination	therapy	with	mirabegron	and	toltero-
dine normalized altered micturition parameters that arose upon in-
duction of inflammation. This was achieved without affecting the 
innate	 contractile	 properties	 of	 the	 bladder.	 Further,	 combination	
therapy	led	to	an	increased	release	of	NO.	It	remains	to	be	investi-
gated if this increased release is a determining factor for the success-
ful pharmacological treatment of symptoms of bladder overactivity. 
With	 a	 cautious	 approach	 to	 suggesting	 clinical	 implications,	 and	
without	taking	potential	side	effects	into	account,	the	findings	in	this	
study indicate that combination therapy may be the best treatment 
option	for	OAB	patients	with	concomitant	cystitis.
ACKNOWLEDG EMENTS
The	 authors	 thank	 Samuel	 Nordin,	 Jennifer	 Clarino	 and	 Lars	
Börjesson	 for	 valuable	 technical	 assistance.	 This	 study	 was	 sup-
ported	 by	 grants	 from	 the	 Colliander	 foundation,	 the	Wilhelm	 &	
Martina	Lundgren	foundation,	the	Royal	Society	of	Arts	and	Sciences	
in	Gothenburg,	and	EPSRC	DTP.
DISCLOSURE
None	of	the	authors	have	any	conflict	to	declare.
AUTHOR CONTRIBUTIONS
Study	design:	MW.	Collection	of	data:	MW,	BP,	FP,	RA.	Analysis,	man-
agement	and	interpretation	of	data:	MW,	BP,	FP,	TC,	PA.	Preparation	
of	manuscript:	MW,	BP,	PA,	TC,	RA.
DECL AR ATION OF TR ANSPARENC Y AND SCIENTIFIC 
RIGOR
This Declaration acknowledges that this paper adheres to the prin-
ciples for transparent reporting and scientific rigor of preclinical 
research	recommended	by	funding	agencies,	publishers,	and	other	
organizations engaged with supporting research.
ORCID
Bhavik Patel  https://orcid.org/0000-0002-8773-3850 
Michael Winder  https://orcid.org/0000-0003-2527-4713 
R E FE R E N C E S
	 1.	 Milsom	 I,	Abrams	P,	Cardozo	 L,	 Roberts	RG,	 Thüroff	 J,	Wein	AJ.	
How widespread are the symptoms of an overactive bladder and 
how	are	they	managed?	A	population-based	prevalence	study.	BJU 
Int.	2001;87:760-766.
	 2.	 Sacco	 E,	 Bientinesi	 R,	 Tienforti	 D,	 et	 al.	 Discovery	 history	 and	
clinical development of mirabegron for the treatment of overac-
tive bladder and urinary incontinence. Expert Opin Drug Discov. 
2014;9:433-448.
	 3.	 Andersson	KE.	Pharmacotherapy	of	the	overactive	bladder.	Discov 
Med.	2009;8:118-124.
	 4.	 Tyagi	 P,	 Tyagi	 V.	 Mirabegron,	 a	 beta(3)-adrenoceptor	 agonist	
for	 the	 potential	 treatment	 of	 urinary	 frequency,	 urinary	 incon-
tinence or urgency associated with overactive bladder. IDrugs. 
2010;13:713-722.
	 5.	 Herschorn	S,	Barkin	J,	Castro-Diaz	D,,	et	al.	A	phase	III,	randomized,	
double-blind,	parallel-group,	placebo-controlled,	multicentre	study	
to	assess	the	efficacy	and	safety	of	the	beta(3)	adrenoceptor	ago-
nist,	mirabegron,	in	patients	with	symptoms	of	overactive	bladder.	
Urology.	2013;82:313-320.
F I G U R E  5  Mean	contractile	responses	to	methacholine	in	rat	detrusor.	Contractile	responses	in	strips	from	(A)	control	bladders	tended	
to	be	slightly	higher	than	in	strips	from	(B)	bladders	with	CYP-induced	cystitis.	No	significant	contractile	differences	could	be	seen	in	either	
control	or	inflamed	strips	when	comparing	responses	between	strips	from	saline	and	drug	pretreated	animals.	Presence	of	the	NO	synthase	
blocker	L-NNA	did	not	significantly	alter	the	contraction-response	curves.	Error	bars	represent	±	SEM.	n	=	6	in	all	groups
(A) (B)
Control
–log [MeCh]
C
on
tr
ac
tio
n 
(m
N)
–9 –8 –7 –6 –5 –4 –3
0
10
20
30
40
Saline pre-treated
Saline pre-treated L-NNA
Drug pre-treated
Drug pre-treated L-NNA
Inflamed
–log [MeCh]
C
on
tr
ac
tio
n 
(m
N)
–9 –8 –7 –6 –5 –4 –3
0
10
20
30
40
Saline pre-treated
Saline pre-treated L-NNA
Drug pre-treated
Drug pre-treated L-NNA
8 of 8  |     PATEL ET AL.
	 6.	 Chapple	 CR,	 Cardozo	 L,	 Nitti	 VW,	 Siddiqui	 E,	 Michel	 MC.	
Mirabegron	in	overactive	bladder:	a	review	of	efficacy,	safety,	and	
tolerability. Neurourol Urodyn.	2014;33:17-30.
	 7.	 Rossanese	M,	Novara	G,	Challacombe	B,	 Iannetti	 A,	Dasgupta	 P,	
Ficarra	V.	Critical	analysis	of	phase	II	and	III	randomised	control	tri-
als	(RCTs)	evaluating	efficacy	and	tolerability	of	a	beta(3)-adreno-
ceptor	agonist	(Mirabegron)	for	overactive	bladder	(OAB).	BJU Int. 
2015;115:32-40.
	 8.	 Gratzke	C,	van	Maanen	R,	Chapple	C,	et	al.	Long-term	safety	and	ef-
ficacy of mirabegron and solifenacin in combination compared with 
monotherapy	 in	 patients	 with	 overactive	 bladder:	 a	 randomised,	
multicentre	phase	3	study	(SYNERGY	II).	Eur Urol.	2018;74:501-509.
	 9.	 Herschorn	S,	Chapple	CR,	Abrams	P,	et	al.	Efficacy	and	safety	of	
combinations of mirabegron and solifenacin compared with mono-
therapy	and	placebo	in	patients	with	overactive	bladder	(SYNERGY	
study).	BJU Int.	2017;120:562-575.
	10.	 Drake	MJ,	 Chapple	C,	 Esen	AA,	 et	 al.	 Efficacy	 and	 safety	 of	mi-
rabegron	 add-on	 therapy	 to	 solifenacin	 in	 incontinent	 overactive	
bladder	 patients	 with	 an	 inadequate	 response	 to	 initial	 4-week	
solifenacin	 monotherapy:	 a	 randomised	 double-blind	 multicentre	
phase	3B	study	(BESIDE).	Eur Urol.	2016;70:136-145.
	11.	 Imran	M,	Najmi	AK,	Tabrez	S.	Mirabegron	for	overactive	bladder:	a	
novel,	first-in-class	beta3-agonist	therapy.	Urol J.	2013;10:935-940.
	12.	 Birder	 LA,	Nealen	ML,	 Kiss	 S,,	 et	 al.	 Beta-adrenoceptor	 agonists	
stimulate	 endothelial	 nitric	 oxide	 synthase	 in	 rat	 urinary	 bladder	
urothelial cells. J Neurosci.	2002;22:8063-8070.
	13.	 Winder	M,	Vesela	R,	Aronsson	P,	Patel	B,	Carlsson	T.	Autonomic	
receptor-mediated	 regulation	 of	 production	 and	 release	 of	 nitric	
oxide	 in	 normal	 and	 malignant	 human	 urothelial	 cells.	 Basic Clin 
Pharmacol Toxicol. 2017;121:257–265.
	14.	 Andersson	MC,	Tobin	G,	Giglio	D.	Cholinergic	nitric	oxide	release	
from	the	urinary	bladder	mucosa	in	cyclophosphamide-induced	cys-
titis of the anaesthetized rat. Br J Pharmacol.	2008;153:1438-1444.
	15.	 Andersson	 M,	 Aronsson	 P,	 Doufish	 D,	 Lampert	 A,	 Tobin	 G.	
Muscarinic	 receptor	 subtypes	 involved	 in	 urothelium-derived	 re-
laxatory	effects	in	the	inflamed	rat	urinary	bladder.	Auton Neurosci. 
2012;170:5-11.
	16.	 Tobin	G,	Sjogren	C.	In	vivo	and	in	vitro	effects	of	muscarinic	recep-
tor antagonists on contractions and release of [3H]acetylcholine in 
the rabbit urinary bladder. Eur J Pharmacol.	1995;281:1-8.
	17.	 Curtis	MJ,	 Alexander	 S,	 Cirino	G,	 et	 al.	 Experimental	 design	 and	
analysis and their reporting II: updated and simplified guidance for 
authors and peer reviewers. Br J Pharmacol.	2018;175:987-993.
	18.	 Faul	F,	Erdfelder	E,	Lang	A-G,	Buchner	A.	G*Power	3:	a	flexible	sta-
tistical	power	analysis	program	for	the	social,	behavioral,	and	bio-
medical sciences. Behav Res Methods.	2007;39:175-191.
	19.	 Andersson	M,	Aronsson	P,	Giglio	D,	Wilhelmson	A,	Jeřábek	P,	Tobin	
G.	Pharmacological	modulation	of	the	micturition	pattern	in	normal	
and	cyclophosphamide	pre-treated	conscious	rats.	Auton Neurosci. 
2011;159:77-83.
	20.	 Ito	K,	Iwami	A,	Katsura	H,	Ikeda	M.	Therapeutic	effects	of	the	puta-
tive	P2X3/P2X2/3	antagonist	A-317491	on	cyclophosphamide-in-
duced cystitis in rats. Naunyn Schmiedebergs Arch Pharmacol. 
2008;377:483-490.
	21.	 Furuta	 A,	 Suzuki	 Y,	 Kimura	 S,	 Koike	 Y,	 Egawa	 S,	 Yoshimura	 N.	
Combination	therapy	with	beta3	-adrenoceptor	agonists	and	mus-
carinic acetylcholine receptor antagonists: efficacy in rats with 
bladder overactivity. Int J Urol.	2016;23:425-430.
	22.	 Sacco	E,	Bientinesi	R,	Bassi	P,	Currò	D.	Pharmacological	methods	
for	 the	preclinical	assessment	of	 therapeutics	 for	OAB:	an	up-to-
date review. Int Urogynecol J.	2016;27:1633-1644.
	23.	 Gur	 S,	 Peak	 T,	 Yafi	 FA,	 Kadowitz	 PJ,	 Sikka	 SC,	 Hellstrom	 WJ.	
Mirabegron	 causes	 relaxation	 of	 human	 and	 rat	 corpus	 caverno-
sum: could it be a potential therapy for erectile dysfunction? BJU 
Int.	2016;118:464-474.
	24.	 Calmasini	FB,	Candido	TZ,	Alexandre	EC,,	et	al.	The	beta-3	adreno-
ceptor	 agonist,	mirabegron	 relaxes	 isolated	prostate	 from	human	
and rabbit: new therapeutic indication? Prostate.	2015;75:440-447.
	25.	 Giglio	D,	Ryberg	AT,	To	K,	Delbro	DS,	Tobin	G.	Altered	muscarinic	
receptor	subtype	expression	and	functional	responses	in	cyclophos-
phamide induced cystitis in rats. Auton Neurosci.	2005;122:9-20.
	26.	 Mossa	A,	Velasquez	Flores	M,	Nguyen	H,	Cammisotto	PG,	Campeau	
L.	Beta-3	adrenoceptor	signaling	pathways	in	urothelial	and	smooth	
muscle cells in the presence of succinate. J Pharmacol Exp Ther. 
2018;367:252-259.
	27.	 Stevens	 LA,	 Sellers	 DJ,	 McKay	 NG,	 Chapple	 CR,	 Chess-Williams	
R.	 Muscarinic	 receptor	 function,	 density	 and	 G-protein	 coupling	
in the overactive diabetic rat bladder. Auton Autacoid Pharmacol. 
2006;26:303-309.
 28. Romih R. Restoration of the rat urothelium after cyclophosphamide 
treatment. Cell Biol Int.	2001;25:531-537.
	29.	 Sawada	N,	Nomiya	M,	Hood	B,	Koslov	D,	Zarifpour	M,	Andersson	
KE.	 Protective	 effect	 of	 a	 beta3-adrenoceptor	 agonist	 on	 blad-
der function in a rat model of chronic bladder ischemia. Eur Urol. 
2013;64:664-671.
How to cite this article:	Patel	B,	Perez	F,	Aronsson	P,	
Alothmani	R,	Carlsson	T,	Winder	M.	Combination	drug	
therapy	against	OAB	normalizes	micturition	parameters	and	
increases	the	release	of	nitric	oxide	during	chemically	
induced cystitis. Pharmacol Res Perspect. 2020;00:e00564. 
https ://doi.org/10.1002/prp2.564
